Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors

被引:540
作者
Lee, S
Jilani, SM
Nikolova, GV
Carpizo, D
Iruela-Arispe, ML [1 ]
机构
[1] Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA
关键词
D O I
10.1083/jcb.200409115
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Vascular endothelial growth factor ( VEGF) is a critical mediator of blood vessel formation during development and in pathological conditions. In this study, we demonstrate that VEGF bioavailability is regulated extracellularly by matrix metalloproteinases ( MMPs) through intramolecular processing. Specifically, we show that a subset of MMPs can cleave matrix-bound isoforms of VEGF, releasing soluble fragments. We have mapped the region of MMP processing, have generated recombinant forms that mimic MMP- cleaved and MMP-resistant VEGF, and have explored their biological impact in tumors. Although all forms induced similar VEGF receptor 2 phosphorylation levels, the angiogenic outcomes were distinct. MMP-cleaved VEGF promoted the capillary dilation of existent vessels but mediated a marginal neovascular response within the tumor. In contrast, MMP-resistant VEGF supported extensive growth of thin vessels with multiple and frequent branch points. Our findings support the view that matrix-bound VEGF and nontethered VEGF provide different signaling outcomes. These findings reveal a novel aspect in the regulation of extracellular VEGF that holds significance for vascular patterning.
引用
收藏
页码:681 / 691
页数:11
相关论文
共 51 条
  • [1] Loss of collagenase-2 confers increased skin tumor susceptibility to male mice
    Balbín, M
    Fueyo, A
    Tester, AM
    Pendás, AM
    Pitiot, AS
    Astudillo, A
    Overall, CM
    Shapiro, SD
    López-Otín, C
    [J]. NATURE GENETICS, 2003, 35 (03) : 252 - 257
  • [2] Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
    Bergers, G
    Brekken, R
    McMahon, G
    Vu, TH
    Itoh, T
    Tamaki, K
    Tanzawa, K
    Thorpe, P
    Itohara, S
    Werb, Z
    Hanahan, D
    [J]. NATURE CELL BIOLOGY, 2000, 2 (10) : 737 - 744
  • [3] PDGF-D is a specific, protease-activated ligand for the PDGF β-receptor
    Bergsten, E
    Uutela, M
    Li, XR
    Pietras, K
    Östman, A
    Heldin, CH
    Alitalo, K
    Eriksson, U
    [J]. NATURE CELL BIOLOGY, 2001, 3 (05) : 512 - 516
  • [4] TACE is required for the activation of the EGFR by TGF-α in tumors
    Borrell-Pagès, M
    Rojo, F
    Albanell, J
    Baselga, J
    Arribas, J
    [J]. EMBO JOURNAL, 2003, 22 (05) : 1114 - 1124
  • [5] Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
    Carmeliet, P
    Ferreira, V
    Breier, G
    Pollefeyt, S
    Kieckens, L
    Gertsenstein, M
    Fahrig, M
    Vandenhoeck, A
    Harpal, K
    Eberhardt, C
    Declercq, C
    Pawling, J
    Moons, L
    Collen, D
    Risau, W
    Nagy, A
    [J]. NATURE, 1996, 380 (6573) : 435 - 439
  • [6] Angiogenesis in cancer and other diseases
    Carmeliet, P
    Jain, RK
    [J]. NATURE, 2000, 407 (6801) : 249 - 257
  • [7] Inflammation and cancer
    Coussens, LM
    Werb, Z
    [J]. NATURE, 2002, 420 (6917) : 860 - 867
  • [8] Damert A, 2002, DEVELOPMENT, V129, P1881
  • [9] Cell-cell interactions in vascular development
    Darland, DC
    D'Amore, PA
    [J]. CURRENT TOPICS IN DEVELOPMENTAL BIOLOGY, VOL 52, 2001, 52 : 107 - 149
  • [10] Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
    Dvorak, HF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) : 4368 - 4380